echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA extends the review period for supplementary new drug applications for AbbVie RINVOQ due to safety considerations

    FDA extends the review period for supplementary new drug applications for AbbVie RINVOQ due to safety considerations

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompileLiLi

    On March 17, according to foreign media reports, AbbVie announced that the US FDA has extended the review period for the anti-inflammatory drug RINVOQ Supplemental New Drug Application (sNDA) for the treatment of active psoriatic arthritis (PsA) in adults.


    AbbVie recently received information from the FDA requesting an updated assessment of the benefit and risk profile of RINVOQ in the treatment of psoriatic arthritis.


    RINVOQ (Upadacitinib) is an oral, once-a-day, selective and reversible JAK inhibitor discovered and developed by AbbVie scientists.


    The drug was successful in a large-scale phase III clinical study for the treatment of adult psoriatic arthritis (PsA) last year.


    The study is a multi-center, randomized, double-blind, parallel-group, positive drug and placebo-controlled phase III study, in 1705 adult patients with psoriatic arthritis (PsA) who had insufficient response to at least one non-biological DMARD It was carried out in China and evaluated the efficacy and safety of two doses of Rinvoq (15mg and 30mg, once a day) relative to placebo and adalimumab.


    The data showed that the study reached the primary endpoint: at week 12, 71% and 79% of patients in the 15mg group and 30mg group achieved ACR20 responses, respectively, and 36% in the placebo group (p<0.


    According to the measurement of HAQ-DI score, patients receiving Rinvoq also showed significant improvement in physical function at week 12: the HAQ-DI scores of patients in the 15mg and 30mg Rinvoq treatment groups changed from baseline by -0.


    In August 2019, RINVOQ was awarded the world's first batch in the United States for use in adult patients with moderate to severe active rheumatoid arthritis (RA) who are inadequate or intolerant to methotrexate.


    The approved dose of RINVOQ for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis is 15 mg.


    The industry is very optimistic about Rinvoq's business prospects.


    In addition, AbbVie has also received a similar request from the FDA for the use of RINVOQ in the treatment of atopic dermatitis to supplement the new drug application.


    Reference source:

    1.


    2.


    3.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.